A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

Cervical cancer continues to be one of the leading causes of cancer-related deaths among women, and the Caribbean region has ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Gardasil pause to China began this month Sales of Keytruda were over $7.8 billion in Q4, compared with analyst forecast of $7.4 billion Gardasil ... demand for the HPV vaccine there is expected ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Gardasil is a vaccine that prevents cancer from HPV ... cats and cattle, posted nearly $1.4 billion in sales, up 9% from the same period a year ago. The company said higher pricing for products ...

Gardasil is a vaccine that prevents cancer from HPV ... a spokesperson said in an email. Merck expects 2% to 4% growth in Gardasil sales, with no further shipments of Gardasil to China at the ...